Valuation: Natera, Inc.

Market Cap 40.28B 35.28B 32.56B 30.08B 57.06B 3,849B 58.11B 390B 152B 1,887B 151B 148B 6,548B P/E 2026 *
-165x
P/E 2027 * -1,181x
Enterprise Value 39.26B 34.38B 31.73B 29.32B 55.61B 3,751B 56.63B 380B 148B 1,839B 147B 144B 6,382B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.7x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day-2.45%
1 week+1.08%
Current month+1.08%
1 month+27.44%
3 months+31.12%
6 months+7.86%
Current year+19.77%
1 week 269.66
Extreme 269.66
288.04
1 month 208.79
Extreme 208.794
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
06-25Free

Director

1,677 0.0012%
06-25Free

Director

1,669 0.0012%
06-25Free

Director

1,691 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-2.45%+1.08%+72.91%+485.18% 40.28B
-2.16%-0.81%+7.71%+33.35% 23.28B
-0.05%+5.00%-19.04%-36.81% 7.49B
-3.30%+6.36%+18.69%+110.22% 5.33B
-1.62%+0.44%+15.84%+40.15% 2.96B
+0.31%-4.41%-23.47%+1,097.45% 1.94B
-1.79%-2.40%+94.80%-9.76% 1.89B
+0.16%-0.16%+29.03%-24.86% 1.68B
+0.06%-0.45%+19.27%-4.40% 1.64B
+0.79%+2.14%-17.71%-68.97% 1.55B
Average -1.00%+0.81%+19.80%+162.15% 8.8B
Weighted average by Cap. -1.96%+2.84%+37.55%+257.91%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.09B 3.96B 267B 4.04B 27.1B 10.55B 131B 10.5B 10.28B 455B 3.33B 2.91B 2.69B 2.48B 4.71B 318B 4.8B 32.22B 12.54B 156B 12.48B 12.21B 541B
Net income -224M -196M -181M -167M -318M -21.41B -323M -2.17B -845M -10.5B -841M -823M -36.43B -25.21M -22.08M -20.38M -18.83M -35.72M -2.41B -36.37M -244M -95.04M -1.18B -94.64M -92.6M -4.1B
Net Debt -1.02B -897M -828M -765M -1.45B -97.83B -1.48B -9.92B -3.86B -47.97B -3.84B -3.76B -166B -1.31B -1.15B -1.06B -979M -1.86B -125B -1.89B -12.7B -4.94B -61.4B -4.92B -4.81B -213B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-08 US$274.39 -2.45% 1,359,691
26-07-07 US$281.27 -0.89% 1,759,681
26-07-06 US$283.80 +1.60% 1,358,559
26-07-02 US$279.32 +1.10% 1,274,247
26-07-01 US$276.27 +1.78% 1,862,134
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
281.27USD
Average target price
266.00USD
Spread / Average Target
-5.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock